Floatz logo

FF 10850

Ovarian Neoplasms

TelikSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

73 Active assets in the Ovarian Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
GlaxoSmithKline
Phase 4BBB
Carboplatin
Eli Lilly and Company
Phase 3BB
(+)-VINCRISTINE
GlaxoSmithKline
Phase 4BB
tlk286
Telik
Phase 3BB
Irinotecan
GlaxoSmithKline
Phase 4BB

View all 50 →

Same molecule, other indications

FF 10850 is also rated in:

Small Cell Lung CancerDormant
B
Indicative ·
56 / 100
View asset →
Ovarian CancerDormant
CCC
Indicative ·
50 / 100
View asset →
Merkel Cell CarcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →